International Medical Journal (ISSN:13412051)

Aim and Scope

Aim-

International Medical Journal ISSN: (13412051) is an international open-access journal publishes twelve times each year. The "International Medical Journal" is a peer-reviewed, monthly, online international research journal, which publishes original articles, research articles, review articles with top-level work from all areas of Medical Science Research and their application including Aetiology, bioengineering, biomedicine, cardiology, chiropody, ENT etc. Researchers in all Medical Science and Pharmacy fields are encouraged to contribute articles based on recent research. Journal publishes research articles and reviews within the whole field of Medical Science and Pharmacy Research, and it will continue to provide information on the latest trends and developments in this ever-expanding subject. International Medical Journal journal covers almost all disciplines of Medical Science and Pharmacy. Researchers and students of M.B.B.S, M.D., D.T.C.D., GYNE., M.S., M.Pharma, And PhD are requested to send their original research articles to International Medical Journal. Azerbaijan Medical Journal Gongcheng Kexue Yu Jishu/Advanced Engineering Science Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery Interventional Pulmonology

Scope-

International Medical Journal ISSN: (13412051) is a peer-reviewed journal. The journal seeks to publish original research articles that are hypothetical and theoretical in its nature and that provide exploratory insights in the following fields but not limited to:

Anatomy Physiology Biochemistry Pharmacology
Pathology Forensic medicine Microbiology Community Medicine
Otorhinolaryngology Internal Medicine General Surgery Obstetrics and Gynecology
Radiology Pulmonary Medicine Dermatology and Venereal diseases Infectious Diseases
Anaesthesia Cancer research Neurosurgery Orthopedics

See More Scopes

Latest Journals
International Medical Journal
Journal ID : IMJ-11-09-2021-928
Total View : 436

Abstract : The current Corona virus disease pandemic (COVID 19) has had a wide-ranging social and economic impact throughout the world. COVID-19 can produce a variety of symptoms ranging from moderate to severe. Hyperactivation of the immune system, particularly the production of pro-inflammatory cytokines like interleukin-6 (IL-6), might be a significant factor in the pathogenesis of COVID-19-related severe illness. The World Health Organization (WHO) has approved the use of Interleukin-6 (IL-6) blockers — tocilizumab and sarilumab — as part of COVID-19 management protocol based on meta-analysis of 27 clinical trials for this drug conducted on 10,000 patients. second drug ever recommended by WHO for COVID-19, will remain unaffordable and inaccessible for most of the world. Around 60 articles were reviewed from the databases PubMed, Scopus, Embase, Web of Science and Google scholar using the key words – SARS CoV 2, cytokine storms, Interleukin, immunomodulators and tocilizumab. Relevant 33 articles were considered for this review. There are no clinical trial results to back up any preventive treatment. There are now over 300 active clinical therapy studies. Tocilizumab (TCZ) is a human monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL-6) to its receptor (IL-6R). It is used to treat inflammatory and autoimmune conditions. Next to dexamethasone, WHO recommended drug for cytokine storm in COVID 19 patients was tocilizumab. Early reports of tocilizumab treatment in COVID-19 patients showed promising results, but little sample sizes questioned their dependability. Treatment with tocilizumab also reported to have favorable changes on CT findings, CRP and IL levels. In contrast, another study has shown administration of tocilizumab did not significantly affect the ICU admission or 7-day mortality rate when compared with the control group. No therapy is approved for COVID-19 pneumonia. Though adverse events have been associated with tocilizumab usage, no conclusive evidence suggests that these were directly attributed to tocilizumab therapy. Also with this available limited data, it could not be assured that tocilizumab has additional benefits on severe COVID affected cases..
Full article
International Medical Journal
Journal ID : IMJ-09-09-2021-926
Total View : 394

Abstract : It is important to reduce amount of bleeding during lower segment caesarean section so as to reduce maternal morbidity due to bleeding. To control bleeding after CS, some medications such as oxytocin, prostaglandins (E1, E2, and F2α), and methylergonovine have been used. Treatment of PPH relies primarily on uterotonics, but early use of tranexamic acid (TXA) has become part of several recommended algorithms. However, the role of IV tranexamic acid has not been effectively evaluated in reducing blood loss during caesarean section, hence the need for this study. Patients with singleton pregnancy and gestational age ≥ 35 weeks were included in the study. Women were randomized into 2 groups- Group I and Group II, for two arm study with 75 subjects in each group. Preoperative haemoglobin was estimated in both the groups. 1-gram dose was chosen for this study. Tranexemic acid was not given to Group 1 while Group 2 were given TXA injection prepared by diluting 1 gram (10ml) TXA in 100ml of normal saline. At the end of the study, the collected data was analyzed. TXA was found to effective in reducing blood loss in study group. Mean blood loss in present study was 529.77 ml in control group and 411.05 ml in TXA group with p value of <0.05. Mean percentage fall in haemoglobin (gm/dl) in control group was 12.19 ± 3.64 which was significantly higher as compared to TXA group (8.93 ± 4.25) with p value of <0.0001. Tranexamic acid was found to be safe and effective in reducing blood loss after LSCS. In the present study, there was less drop in haemoglobin and haematocrit in tranexamic acid group. Tranexamic acid was not associated with any severe adverse drug reactions like thrombosis and hence it can be safely used for prevention of PPH. It was concluded that Tranexamic acid, plays a beneficial role in preventing PPH and maternal mortality..
Full article
International Medical Journal
Journal ID : IMJ-07-09-2021-925
Total View : 396

Abstract : The current Corona virus disease pandemic (COVOD 19) has had a wide-ranging social and economic impact throughout the world. The present COVID-19 epidemic has prompted scientists throughout the world to look for remedies in terms of SARS-CoV-2 treatments and vaccines. Since the genomic sequence of SARS-CoV-2 was published on January 11th, 2020, an unprecedented effort to create a vaccine against the disease has been underway. On January 5th, 2021, the World Health Organization (WHO) reported that there are 63 candidate vaccines in human clinical trials and more than 172 candidates in preclinical development throughout the world. In this review, around 60 articles and newsletters were reviewed from the internet source and databases like PubMed, Scopus, Google Scholar, Embase using the key words novel corona virus, SARS CoV 2 structure, vaccines, treatment, recent advances, clinical trials. A simple concise review is written based on around 40 articles..
Full article
International Medical Journal
Journal ID : IMJ-07-09-2021-924
Total View : 463

Abstract : Diabetes mellitus is a metabolic disease whose incidence is growing at an alarming rate worldwide, especially in developing nations. According to the World Health Organization, diabetes would rank seventh among the major causes of death by 2030. Plants have been used to treat and prevent disease for thousands of years, and they are the source of many current medications. A natural product such as the Onodiab capsule, whose ingredients include Smallanthus sonchifolius, Camellia sinensis, Syzygium polyanthum, and Stevia rebaudiana, is one of the natural commodities. This review provides information on antidiabetic plants that has been gathered from various literature sources and databases. According to the findings of this study, the majority of the plants exhibit antidiabetic effects in some form. The hypoglycemic action of this plant may be found in a variety of components of the plant, including the leaves, rhizomes, fruit, bark, seeds, and other portions that vary from one species to another. In addition, it is clear from this analysis that the mechanism of action and the dosage required for administration differ from one plant to another..
Full article
International Medical Journal
Journal ID : IMJ-06-09-2021-923
Total View : 366

Abstract : For years, endotracheal tube intubation and bag mask ventilation were the mainstays of airway management. The invention of LMA by Dr. Archie Brain had a great impact on the practice of anesthesia in paediatrics. The recently introduced Proseal LMA with a rear cuff and drainage tube that allows a higher pressure and permits drainage of gastric secretions, preventing the pulmonary aspiration. In our study the ProSeal LMA is compared with ETT with respect to complications in pediatric patients. Prospective Double Blind Randomized Comparative Study was conducted on 60 ASA I and II paediatric patients, weighing 5-25kg between 2 to 10 years of age group of either sex scheduled for elective surgeries. They were randomly divided into 30 patients of either PLMA (Group P) or ET (Group E). Perioperative complications were recorded from baseline till end of surgery and 24 hours postoperatively. The statistical analysis was done using SPSS version 20.0. PLMA showed lesser post-operative airway related complications like coughing, sore throat, hoarseness of voice and bronchospasm than ETT..
Full article

Our Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
Certificates
//